According to a study from the U.S. Food and Drug Administration (FDA), Pradaxa (dabigatran), in comparison to warfarin, was associated with a lower risk of stroke and death, but an increased risk of major gastrointestinal bleeding. The risk for myocardial infarction was similar for the two drugs. In a statement, the FDA said, “[W]e still consider Pradaxa to have a favorable benefit to risk profile and have made no changes to the current label or recommendations for use.” Read more.
© 2021 HealthCom Media All rights reserved. No part of this website or publication may be reproduced, stored, or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the copyright holder